Admin
... Read More
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Policy.
Written By: Admin | Updated : February 21, 2014 8:39 PM IST
Washington, June 19 (ANI): A new study suggests that aspirin can lower our cancer risk by lowering the rate of accumulation of DNA mutations in abnormal cells which is a pre-cancerous condition. Aspirin and other NSAIDs which are commonly available may exhibit similar cancer-preventing effects.
Lead author Maley, working with gastroenterologist and geneticist Brian Reid, MD, PhD, of the Fred Hutchinson Cancer Research Center, analysed biopsy samples from 13 patients with a pre-cancerous condition called Barrett's oesophagus who were tracked for six to 19 years. In an 'observational crossover' study design, some patients started out taking daily aspirin for several years, and then stopped, while others started taking aspirin for the first time during observation. The goal was to track the rate of mutations in tissues sampled at different times.
The researchers found that biopsies taken while patients were on an aspirin had on average accumulated new mutations about 10 times more slowly than biopsies obtained during years when patients were not taking aspirin. Gender and ethnic distribution of study patients reflected the known demographics of oesophageal cancer, which predominantly affects, white, middle-aged and elderly men, he said. Barrett's oesophagus only occasionally progresses to oesophageal cancer.
Maley said that less inflammation may result in less production within pre-cancerous tissue of oxidants known to damage DNA, and may dampen growth-stimulating signalling. For the duration of the study, the rate of accumulation of mutations measured in the biopsied tissue between time points was slow, even when patients were not taking aspirin, with the exception of one patient.
While mutations accumulated at a steady rate, the vast majority of mutations arose before the abnormal tissue was first detected in the clinic, the researchers concluded. In the one patient who later went on to develop cancer, a population of cellular 'clones' with a great number of mutations emerged shortly before he started taking aspirin. The study has been published online in journal PLOS Genetics.
